Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies: Part 3: Extending the Imatinib Paradigm (22:09)

submitted by: scivee-team

The lessons learned from the clinical trials of imatinib will be reviewed in this section. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades.

Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies: Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12)

submitted by: scivee-team
Although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this...

Adhesion, Signaling and Cancer: Part 3: Focal Adhesions as Stress Sensors (30:57)

submitted by: scivee-team
In the third segment of my seminar, I address a new frontier in cell biology, that is how cells respond to mechanical information. Cells and tissues are exposed to physical forces in vivo and excessive mechanical stress leads to a variety of pathological consequences. I describe a system for exposing cells to controlled mechanical stress and discuss the stretch response. We have discovered that the focal adhesion protein, zyxin, is exquisitely sensitive to mechanical stimulation and is...

Adhesion, Signaling and Cancer: Part 2: Discovery and Characterization of a Focal Adhesion Protein Implicated in Tumor Progression (50:54)

submitted by: scivee-team

In the second segment, I describe the identification of the focal adhesion protein, zyxin, by my lab. Recent work revealed that zyxin is down-regulated upon expression of the Ewing sarcoma oncoprotein, EWS-FLI. Loss of zyxin expression results in enhanced cell motility and is also associated with failed apoptotic signaling. Evidence that zyxin shuttles between focal adhesions and the nucleus is presented. The impact of reduced zyxin expression on tumor progression is discussed.

Apoptosis: Part 3: Extrinsic Pathway and Regulation of Apoptosis (23:59)

submitted by: scivee-team
Apoptosis a form of programmed cell death that plays important roles during animal development, immune response, elimination of damaged cells, and maintenance of tissue homeostasis. Apoptosis is executed by intracellular proteases named caspases that are activated during the onset of apoptosis by extrinsic and intrinsic pathways. The intrinsic pathway is triggered by the release of proteins such as cytochrome c from mitochondria to cytosol and the extrinsic pathway is activated by the...

Apoptosis: Part 2: Factors Involved in the Intrinsic Pathway of Apoptosis (27:39)

submitted by: scivee-team
Apoptosis a form of programmed cell death that plays important roles during animal development, immune response, elimination of damaged cells, and maintenance of tissue homeostasis. Apoptosis is executed by intracellular proteases named caspases that are activated during the onset of apoptosis by extrinsic and intrinsic pathways. The intrinsic pathway is triggered by the release of proteins such as cytochrome c from mitochondria to cytosol and the extrinsic pathway is activated by the...